Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)Reported by Chris Markoch. Date Posted: 1/18/2026. 
Quick Look - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities. These bets typically target companies with disruptive technologies, exposure to emerging trends, or compelling turnaround stories. Many of these firms will never scale, but a single successful idea can produce outsized returns. For investors who favor crowd signal, MarketBeat provides a tool that lists the 100 Most Popular Penny Stocks, ranked by the number of MarketBeat subscribers following each company. That popularity is not a guarantee of success, but it can help investors gain conviction in a stock's potential. Gold has weathered every financial disaster in history, and it's up more than 100 percent in the last two years. But there's another reason to pay attention now. Since 1950, roughly 70 percent of all the gold on earth has already been mined. What remains is harder to find and more costly to extract. Supplies are running out at the exact moment the world needs gold to stabilize heavily indebted financial systems. A four-stock portfolio of top gold developers is now available, selling at an average 82 percent discount to asset value. Get the four picks plus a bonus stock with potential for significant upside. Some investors define a penny stock as any share trading at $5 or less. The stocks in this screener follow the traditional definition: shares priced below $1. These names are highly volatile — conduct your own research and be clear about your risk tolerance before initiating a position. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases such as influenza, norovirus, and COVID-19. Unlike traditional injectable vaccines, Vaxart's tablet-based platform aims to simplify distribution and improve global accessibility. The bull case for Vaxart centers on that innovation. If the company secures FDA approval and successfully scales production, its oral vaccines could reduce logistical barriers to mass immunization and create significant licensing opportunities. Positive trial results or a commercial collaboration could materially change sentiment and valuation from the stock's current low base. Clinical and regulatory risk remain the biggest challenges. Vaxart has not yet brought a product to market, and vaccine development is expensive and unpredictable. Competition from established players with larger R&D budgets also constrains visibility. For now, Vaxart is a long-term speculative bet on platform validation rather than near-term profitability. MarketBeat analyst coverage of Vaxart is minimal — only a single analyst — which is not unusual for micro-cap names but should prompt investor caution. Institutional ownership stands at roughly 18%. On a more positive note, the stock has about 2% short interest, which may modestly reduce some volatility relative to heavily shorted micro-caps. Microvision: Developing Cost-Effective LiDAR Units For Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors for autonomous vehicles, smart infrastructure, and industrial sensing. Its hardware and software solutions enable precise 3D mapping required for self-driving systems and advanced driver-assistance systems (ADAS). Microvision focuses on compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bull case rests on two factors: the ongoing push toward vehicle automation and the potential for partnerships with major automotive manufacturers. If Microvision can demonstrate performance or cost advantages, it could land supply agreements or licensing deals that materially improve revenue visibility. The company's technology may also find applications in robotics and smart-city projects, adding optionality to its growth story. That said, Microvision faces stiff competition from LiDAR players such as Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ), and Ouster (NYSE: OUST). The path to profitability is uncertain, and repeated delays in LiDAR adoption continue to frustrate investors. MVIS is covered by three analysts and carries a consensus price target of $2.50 — roughly a 169% premium to its Jan. 15 closing price. Like many speculative names, Microvision shows relatively low institutional ownership (around 30%) and elevated short interest (about 21%), which contributes to high volatility. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates where artificial intelligence, data monetization, and digital asset management intersect. The company helps organizations convert raw data into tradable, revenue-generating assets via its patented Datavault platform. By combining AI, blockchain, and analytics, Datavault AI aims to democratize data ownership and unlock monetization channels that many legacy systems miss. The bullish thesis for Datavault AI is its niche focus and potential scalability. As data grows in value, businesses — and potentially individuals — are seeking secure ways to monetize digital information. Datavault's platform could benefit from broader AI adoption and rising interest in data sovereignty. Early-stage traction or strategic partnerships could provide meaningful upside. However, Datavault AI operates in a highly experimental area. Its business model is still evolving, and a clear path to significant revenue remains unproven. Institutional ownership is under 1%, and short interest exceeds 16% at the time of writing. Investors should view DVLT as a long-term, speculative position based on belief in the data-as-an-asset thesis rather than near-term earnings potential.
| 
